Tidal Trust II YieldMax Target 12 Semiconductor Option Income ETF (ARCA: SOXY)

Dernières nouvelles pour Tidal Trust II YieldMax Target 12 Semiconductor Option Income ETF (ARCA:SOXY)

YieldMax Target 12 Semiconductor Option Income ETF

Tidal Trust II YieldMax Target 12 Semiconductor Option Income ETF

On January&nbsp;8, 2025, Climb Bio, Inc. (the "Company") entered into a technology transfer and exclusive license agreement (the "Agreement") with Beijing Mabworks Biotech Co., Ltd. ("Mabworks"), pursuant to which Mabworks granted to the Company (1)&nbsp;an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the "Licensed Intellectual Property") to develop, manufacture and commercialize Mabworks' proprietary antibodies associated with Mabworks' proprietary antibody program identified as MIL116 (the "Licensed Compounds" or "CLYM116") and products containing the Licensed Compounds ("Licensed Products") outside of China, Hong Kong, Macau, and Taiwan (the "Licensed Territory"), (2) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in China, Hong Kong, Macau, and Taiwan (the "China Territory") and (3)&nbsp;a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the China Territory in connection with certain global clinical studies (as described below).
Under the terms of the Agreement, the Company is obligated to pay to Mabworks a $9.0&nbsp;million upfront payment, a total of up to $30.0&nbsp;million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $832&nbsp;million upon the achievement of certain commercial milestones for all Licensed Products. In addition, the Company is obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory.

Biotech

General

CLYM

Climb Bio Entered Technology Transfer And Exclusive License Agreement With Beijing Mabworks Biotech Co.; Climb Obligated To Pay Mabworks $9M Upfront And Up To $30M On Milestones, With Total Up To $832M Upon Achievement Of Certain Milestones For All Licensed Products

Netcapital Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>, NPCLW))), a digital private capital markets ecosystem, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 270,861 shares of common stock of the Company originally issued in December 2023 and May 2024, having an exercise price of $10.85 per share, at a reduced exercise price of $1.80 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282590). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $487,549, prior to deducting placement agent fees and estimated offering expenses.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A-5 warrants to purchase up to 361,148 shares of common stock and new unregistered Series A-6 warrants to purchase up to 180,574 shares of common stock. The Series A-5 new warrants will have an exercise price of $2.07 per share, will be exercisable six months after issuance, and will expire five years thereafter. The Series A-6 new warrants will have an exercise price of $2.07 per share, will be exercisable six months after issuance and will expire eighteen months thereafter.
The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general working capital purposes.

News

Offerings

NCPL

Netcapital Announces Definitive Agreements for Exercise of 270,861 Warrants at Reduced Price of $1.80/Share, Anticipates Gross Proceeds of $487,549

<ul>
<li>Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million</li>
<li>Placement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024</li>
<li>Lantheus shareholding in Radiopharm increases to 12.16% following the placement</li>
<li>The funds raised will be applied to the development of Radiopharm's clinical pipeline</li>
</ul>
SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has executed a subscription agreement for a private placement of ordinary shares to Lantheus Holdings Inc. ( "Lantheus"), raising US$5.0 million (A$8.0 million).
The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur within 7 days.
The placement replaces 6-month options that the Company issued in August 2024 (see ASX announcement 20 June 2024).

Contracts

LNTH

RADX

Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M

FORR

Forrester Research Announced 6% Workforce Reduction, Expects Pre-Tax Expenses $5.2M-$5.6M

Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) will release earnings for its fourth quarter, before the <a href="https://www.benzinga.com/quote/BAC/earnings">opening bell on Thursday, Jan. 16.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at 77 cents per share. That&#8217;s up from 35 cents per share in the year-ago period. According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Bank of America projects quarterly revenue of $25.09 billion, compared to $21.96 billion a year earlier.
On Jan. 7, UBS analyst Erika Najarian upgraded Bank of America from Neutral to Buy and announced a $53 price target.
With the recent buzz around Bank of America, some investors may be eyeing potential gains from the company's dividends too. Bank of America currently offers an annual dividend yield of 2.25%, or a quarterly dividend of 26 cents per share ($1.04 a year).
To figure out how to earn $500 monthly from Bank of America, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Bank of America's $1.04 dividend: $6,000 / $1.04 = 5,769 shares.
So, an investor would need to own approximately $266,585 worth of Bank of America, or 5,769 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.04 = 1,154 shares, or $53,326 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
BAC Price Action: Shares of Bank of America gained by 0.3% to close at $46.21 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Bank of America Stock Ahead Of Q4 Earnings

Findings show significant brain activity after a single 20mg dose of SP-624 in healthy subjects
Phase 2b/3 study of SP-624 in major depressive disorder is underway
SP-624 has the potential to be the first treatment specifically for females with Major Depression
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arrivobio.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Arrivo+BioVentures&amp;index=1&amp;md5=b26643e71e80d6b6dbb548fa286adb84">Arrivo BioVentures</a> today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies.
Arrivo's SP-624-103 study is a double blind, placebo-controlled study with three cohorts. Cohort 1 is comprised of 12 healthy subjects (8 active, 4 placebo) who received 20mg of SP-624 over a 15-day dosing period. Assessments, including quantitative EEG (qEEG) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffireflyneuro.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Firefly+Neuroscience%26%238217%3Bs&amp;index=2&amp;md5=faf584bd97e07c7f189d793410dbf3cb">Firefly Neuroscience's</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FAIFF%2F&amp;,%20esheet=54176223&amp;,%20newsitemid=20250110201020&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+AIFF&amp;,%20index=3&amp;,%20NASDAQ:%3Ca%20class=">AIFF</a>) brain network analytics (BNA&#x2122;), were performed at Day One and Day 15 pre- and post-dose. Cohort 2 is actively enrolling 12 patients diagnosed with major depressive disorder (MDD). The subject composition of the 3rd cohort will be determined after the completion of the second cohort.
Cohort 1 results of the SP-624-103 study include:
<ul>
<li>Subjects showed an increase in beta power, particularly in the frontal-central regions compared to patients taking placebo after a single dose, suggesting enhanced synaptic plasticity and neuronal connectivity.</li>
<li>Subjects showed a decrease in delta power. This is important as increases in delta activity are often associated with reduced cortical arousal and depressive states.</li>
<li>Evoked potential response findings suggest enhanced neural efficiency in early perceptual processing and improved decision-making speed and context updating.</li>
</ul>

AIFF

Arrivo BioVentures Announces Brain Activity Increase With Single 20mg SP-624 Dose In Healthy Subjects; Phase 2b/3 Trial For Major Depression In Progress; Potential First Treatment For Females With Major Depression; Enhanced Synaptic Plasticity And Neuronal Connectivity Observed

Management

ROLR

High Roller Technologies Appoints Kristofer Muscat As Chief Operating Officer

<ul>
<li>The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma &nbsp;</li>
<li>Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients &nbsp;</li>
<li>Seven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple Negative Breast Cancer ("TNBC"), and several patients have been treated</li>
</ul>
SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4335946-1&amp;h=1845873411&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a>&nbsp;("Intensity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.&nbsp;

INTS

Intensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients

NXTC

NextCure Doses First Patient Dosed In Phase 1 Study Of LNCB74 (For Treating Multiple Cancers

INZY

Inozyme Pharma Announces Interim Data For INZ-701 in Infants And Young Children wWth ENPP1 Deficiency, Showing Improvements From Baseline In Multiple Measures Of Disease

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 –
– Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 –
– REV102, an ENPP1 Inhibitor for the Treatment of Hypophosphatasia, to Enter IND-Enabling Studies in 2025 –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025.

RLYB

Rallybio Highlights 2024 Achievements; Announces 2025 Milestones, RLYB212 Phase 2 Participant Dosing In Q2 2025, RLYB116 PK/PD Study Launch In Q2 2025, REV102 IND-Enabling Studies Planned For 2025; FNAIT Study Screening To Conclude January 2025.

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $29 to $40.

Price Target

Analyst Ratings

EXEL

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $40

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 -
- IND application for CRG-023, CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 -
- CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while leveraging existing autologous drug product processes -&nbsp; &nbsp;
 SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ARZMJrK8j2BjKZzS_L10hQx5YAo4VCSXKkxHEiE4gMCdpf6MR9EnLIv9y1XRPZkFK1RH_JTLy8h9_CM7AuErzA3FqHObWkzEp5_hPSseszA=">CARGO Therapeutics, Inc</a>. (NASDAQ:<a href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today provided a corporate update and anticipated milestones for 2025.

CRGX

CARGO Therapeutics Reports 71 Patients Dosed In Phase 2 Firicabtagene Autoleucel Study; Interim Results Expected H1'25; FDA Clears IND For CRG-023, Phase 1 Enrollment Mid-2025; Announces Novel Allogeneic Platform For CAR T-Cell Therapy

CASH

CASK

CORRECTION: Heritage Distilling Ticker Is 'CASK'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Heritage Distilling Board Approves Bitcoin Treasury Policy

Guidance

TD SYNNEX Sees Q1 Adj. EPS $2.65 - $3.15 vs $2.95 Est., Revenue $14.4B - $15.2B vs $14.769B Est.

The Company reported the following results on a preliminary and unaudited basis2:
<ul>
<li>Net sales for the fourth quarter increased 5.0% to $402.0 million</li>
<li>Constant currency net sales3 for the fourth quarter increased 6.0% to $405.9 million, with the United States ("U.S.") increasing 10.5% and Canada decreasing 0.2%</li>
<li>Comparable store sales for the fourth quarter increased 1.6%, with the U.S. increasing 4.7% and Canada decreasing 2.5%</li>
<li>Net sales for fiscal 2024 increased 2.5% to $1.54 billion</li>
<li>Constant currency net sales3 for fiscal 2024 increased 3.1% to $1.55 billion, with the U.S. increasing 6.7% and Canada decreasing 1.6%</li>
<li>Comparable store sales for fiscal 2024 decreased 0.1%, with the U.S. increasing 2.7% and Canada decreasing 4.0%</li>
</ul>
Based on the preliminary fourth quarter and fiscal 2024 net sales results outlined above, the Company reaffirms its previously provided fiscal 2024 Adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA")1 outlook of approximately $290 million to $300 million.

Company Reports Q4 Net Sales Up 5% To $402M; U.S. Sales Rise 10.5%, Canada Falls 0.2%; Fiscal 2024 Sales Up 2.5% To $1.54B; Reaffirms EBITDA Outlook Of $290M-$300M

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

CPRX

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini –
-- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) –
-- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out --
-- Year end, unaudited, cash balance of $835 million following oversubscribed public offering in December 2024 --
NAARDEN, The Netherlands and MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today provided an update on the obicetrapib clinical development program and outlined its strategic priorities for 2025.
NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.&nbsp;The Company's global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients.

NAMS

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT & REMBRANDT Trials To Conclude In 2025, 2027.

INSM

Insmed Provides Outlook Ahead Of J.P. Morgan Healthcare Conference; Sees 2025 Global ARIKAYCE Revenues $405M-$425M

The universe of high-yield, option strategy ETFs continues to explode, with new funds launching every week.

Comments

Tidal Trust II YieldMax Target 12 Semiconductor Option Income ETF

Actualités

Dernières nouvelles pour Tidal Trust II YieldMax Target 12 Semiconductor Option Income ETF (ARCA:SOXY)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL